Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY G ALLEN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1043217250
CMS profile
228111
Location
CRANSTON, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$9,766.81

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $9,266.09 28
Allergan, Inc. $400.00 1
PFIZER INC. $53.73 4
Novo Nordisk Inc $32.27 1
Amgen Inc. $14.72 1

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY G ALLEN

NPI 1043217250 · CMS profile ID 228111

Allopathic & Osteopathic Physicians / Internal Medicine

CRANSTON, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043217250?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY G ALLEN, NPI 1043217250, CMS profile ID 228111. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043217250?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGORY G ALLEN, NPI 1043217250, CMS profile ID 228111. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043217250?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGORY G ALLEN, NPI 1043217250, CMS profile ID 228111, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043217250?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $9,766.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $27.4512/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857131 CMS
AbbVie Inc. $1,440.0012/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857135 CMS
AbbVie Inc. $6.2411/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857127 CMS
AbbVie Inc. $10.4810/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857123 CMS
AbbVie Inc. $17.2210/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857119 CMS
AbbVie Inc. $4.6910/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857115 CMS
AbbVie Inc. $1,750.0010/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857111 CMS
AbbVie Inc. $17.6709/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857103 CMS
AbbVie Inc. $13.0009/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857107 CMS
AbbVie Inc. $15.1808/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857095 CMS
AbbVie Inc. $3.4408/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857099 CMS
AbbVie Inc. $20.2007/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857091 CMS
PFIZER INC. $14.3107/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833422375 CMS
AbbVie Inc. $2.0506/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857079 CMS
AbbVie Inc. $1,920.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857083 CMS
AbbVie Inc. $28.0806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857087 CMS
AbbVie Inc. $20.5306/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857075 CMS
PFIZER INC. $11.1006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833514465 CMS
AbbVie Inc. $17.7206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857071 CMS
PFIZER INC. $17.0606/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833425073 CMS
AbbVie Inc. $15.0805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857067 CMS
Novo Nordisk Inc $32.2705/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810950767 CMS
AbbVie Inc. $17.1205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857059 CMS
AbbVie Inc. $1,920.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857063 CMS
AbbVie Inc. $14.9605/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857055 CMS
AbbVie Inc. $1,920.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857051 CMS
Amgen Inc. $14.7204/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825338785 CMS
AbbVie Inc. $4.6104/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857047 CMS
AbbVie Inc. $16.2503/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857043 CMS
PFIZER INC. $11.2603/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833382519 CMS
AbbVie Inc. $14.2303/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857039 CMS
AbbVie Inc. $16.9102/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857035 CMS
AbbVie Inc. $8.2001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857031 CMS
Allergan, Inc. $400.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792686133 CMS
AbbVie Inc. $4.7801/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793857027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,566.53 160
PY2020 $15,313.61 85
PY2021 $9,766.81 35
PY2022 $5,311.18 16
PY2023 $650.58 37
PY2024 $929.01 50
PY2025 $2,387.96 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,000.00 8
PY2024 Principal investigator $2,589,658.00 47
PY2023 Principal investigator $2,938,018.07 32
PY2022 Principal investigator $1,628,606.23 30
PY2021 Principal investigator $2,692,436.56 26
PY2020 Principal investigator $1,742,352.76 43
PY2019 Principal investigator $151,779.91 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $925.00 12/31/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
(GOULD): a Registry of High Cardiovascular Risk Subjects in the United States No dispute reported 06/30/2026 731634067
Principal investigator 1 AKEBIA THERAPEUTICS INC $778.50 12/23/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287229
Principal investigator 1 Quidel Corporation $176,963.68 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548039
Principal investigator 1 Quidel Corporation $227,265.00 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548041
Principal investigator 1 Quidel Corporation $67,270.44 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548043
Principal investigator 1 Quidel Corporation $149,691.88 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548045
Principal investigator 1 Quidel Corporation $149,650.00 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548047
Principal investigator 1 Quidel Corporation $87,750.00 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548049
Principal investigator 1 Quidel Corporation $69,000.00 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548051
Principal investigator 1 Quidel Corporation $147,250.00 12/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548053
Principal investigator 1 AKEBIA THERAPEUTICS INC $225.00 11/12/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286687
Principal investigator 1 Quidel Corporation $52,800.00 11/12/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548011
Principal investigator 1 Quidel Corporation $54,400.00 11/12/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548013
Principal investigator 1 Quidel Corporation $41,300.00 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547999
Principal investigator 1 Quidel Corporation $36,650.00 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548001
Principal investigator 1 Quidel Corporation $31,514.08 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548003
Principal investigator 1 Quidel Corporation $48,700.00 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548005
Principal investigator 1 Quidel Corporation $67,100.00 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548007
Principal investigator 1 Quidel Corporation $30,302.00 11/05/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752548009
Principal investigator 1 Quidel Corporation $42,000.00 10/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547979
Principal investigator 1 Quidel Corporation $29,250.00 10/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547981
Principal investigator 1 Quidel Corporation $46,672.78 10/22/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547985
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 10/21/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286583
Principal investigator 1 Quidel Corporation $87,750.00 10/15/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547973
Principal investigator 1 Quidel Corporation $72,736.70 10/15/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH, LLC
SARS No dispute reported 06/30/2026 752547975
Principal investigator 1 AKEBIA THERAPEUTICS INC $225.00 09/11/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286365
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 09/09/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286351
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 08/10/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286083
Principal investigator 1 PFIZER INC. $6,000.00 07/17/2020 Non-covered Recipient Entity
Center for Medical Research LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 742940499
Principal investigator 1 AKEBIA THERAPEUTICS INC $225.00 07/09/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285395
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 07/07/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285375
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 06/16/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284775
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,297.80 06/02/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284297
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 05/12/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283833
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,335.60 05/04/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283359
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,599.30 03/18/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282365
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 03/09/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753281967
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,001.60 02/24/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289201
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 02/12/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288827
Principal investigator 1 AKEBIA THERAPEUTICS INC $788.40 02/11/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288763
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,400.10 02/04/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288437
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,240.90 01/08/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287791
Principal investigator 1 AKEBIA THERAPEUTICS INC $441.00 01/02/2020 Non-covered Recipient Entity
CENTER FOR MEDICAL RESEARCH LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284321